- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07684638
Self-Compassion and Quality of Life in Nursing Students With Premenstrual Syndrome
20. juli 2026 oppdatert av: Güzin Ünlü Suvari, Acibadem University
The Mediating Role of Self-Compassion in the Association Between Premenstrual Symptom Severity and Premenstrual Syndrome-Specific Quality of Life Among Nursing Students With Premenstrual Syndrome
Premenstrual syndrome (PMS) is one of the most common menstrual disorders among women of reproductive age and is characterized by recurrent physical, emotional, cognitive, and behavioral symptoms during the late luteal phase of the menstrual cycle.
These symptoms may adversely affect academic performance, daily functioning, interpersonal relationships, and quality of life.
Although previous studies have demonstrated that greater premenstrual symptom severity is associated with poorer quality of life, the psychological mechanisms underlying this relationship remain unclear.
Self-compassion, defined as a compassionate and nonjudgmental attitude toward oneself during times of difficulty, has been identified as a protective psychological factor associated with better emotional well-being and adaptive coping.
However, its mediating role in the relationship between premenstrual symptom severity and premenstrual syndrome-specific quality of life has not been adequately investigated.
This cross-sectional study aims to examine the association between premenstrual symptom severity and premenstrual syndrome-specific quality of life and to investigate the mediating role of self-compassion among nursing students who meet the study criteria for PMS (Premenstrual Syndrome Scale score ≥110).
Studieoversikt
Status
Fullført
Studietype
Observasjonsmessig
Registrering (Faktiske)
164
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Ataşehir
-
Istanbul, Ataşehir, Tyrkia (Türkiye)
- Acibadem University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Female undergraduate nursing students aged 18-25 years with premenstrual syndrome, defined as a Premenstrual Syndrome Scale (PMSS) score of 110 or higher, who meet the study eligibility criteria.
Beskrivelse
Inclusion Criteria:
- Female nursing students aged 18 to 25 years.
- Regular menstrual cycles.
- Premenstrual Syndrome Scale (PMSS) total score of 110 or higher, indicating premenstrual syndrome according to the established cut-off value.
- Willingness to participate and provide written informed consent.
Exclusion Criteria:
- Receiving ongoing physician-prescribed pharmacological treatment for premenstrual syndrome (e.g., oral contraceptives, hormonal therapy, or selective serotonin reuptake inhibitors).
- Irregular menstrual cycles.
- History of chronic medical disease.
- History of psychiatric disorders.
- Incomplete study questionnaires.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Nursing Students Meeting the Study Criteria for PMS
Female nursing students aged 18-25 years with Premenstrual Syndrome Scale (PMSS) scores ≥110 who meet the study eligibility criteria.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sociodemographic, Menstrual, and Lifestyle Characteristics
Tidsramme: Baseline
|
Sociodemographic, menstrual, reproductive, and lifestyle characteristics will be collected using a researcher-developed questionnaire consisting of 20 items.
The questionnaire includes information on age, academic year, menstrual history, menstrual pain characteristics, premenstrual syndrome history, analgesic use, sleep characteristics, caffeine consumption, fast-food consumption, sugar intake, and other lifestyle-related factors.
|
Baseline
|
|
Premenstrual Syndrome Scale (PMSS)
Tidsramme: Baseline
|
Premenstrual symptom severity will be assessed using the Premenstrual Syndrome Scale (PMSS).
The PMSS is a 44-item self-report instrument consisting of nine subscales (depressive affect, anxiety, fatigue, irritability, depressive thoughts, pain, appetite changes, sleep changes, and bloating).
Total scores range from 44 to 220, with higher scores indicating greater premenstrual symptom severity.
In accordance with the original scale, a total PMSS score of 110 or higher, representing the established cut-off for premenstrual syndrome, will be used as an eligibility criterion for study enrollment.
|
Baseline
|
|
Premenstrual Syndrome-Specific Quality of Life Scale (PMS-QoL)
Tidsramme: Within approximately 1 week after baseline
|
Premenstrual syndrome-specific quality of life will be assessed using the Premenstrual Syndrome-Specific Quality of Life Scale (PMS-QoL).
The PMS-QoL is a 22-item self-report instrument consisting of three domains: physical well-being, emotional well-being, and social well-being.
Higher scores indicate better premenstrual syndrome-specific quality of life.
|
Within approximately 1 week after baseline
|
|
Self-Compassion Scale (SCS)
Tidsramme: Within approximately 1 week after baseline
|
Self-compassion will be assessed using the Self-Compassion Scale (SCS).
The SCS is a 26-item self-report instrument comprising six dimensions: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification.
Higher scores indicate greater self-compassion.
|
Within approximately 1 week after baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Neff, K. D. (2003). Development and validation of a scale to measure self- compassion. Self and Identity, 2(3), 223-250.
- Branecka-Wozniak D, Cymbaluk-Ploska A, Kurzawa R. The impact of premenstrual syndrome on women's quality of life - a myth or a fact? Eur Rev Med Pharmacol Sci. 2022 Jan;26(2):598-609. doi: 10.26355/eurrev_202201_27887.
- Victor FF, Souza AI, Barreiros CDT, Barros JLN, Silva FACD, Ferreira ALCG. Quality of Life among University Students with Premenstrual Syndrome. Rev Bras Ginecol Obstet. 2019 May;41(5):312-317. doi: 10.1055/s-0039-1688709. Epub 2019 Jun 10.
- American College of Obstetricians and Gynecologists. (2023). Premenstrual syndrome (PMS). https://www.acog.org/womens-health/faqs/premenstrual-syndrome
- Guldu, E. T. C., & Canbay, F. C. (2025). Prevalence and risk factors of premenstrual syndrome in Turkey: A systematic review and meta-analysis. International Journal of Caring Sciences, 18(1), 190.
- Celik B, Tektas P. Self-compassion and premenstrual syndrome symptoms in women: a descriptive correlational study. BMC Womens Health. 2026 Feb 12;26(1):166. doi: 10.1186/s12905-026-04338-w.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
26. juni 2026
Primær fullføring (Faktiske)
15. juli 2026
Studiet fullført (Faktiske)
15. juli 2026
Datoer for studieregistrering
Først innsendt
29. juni 2026
Først innsendt som oppfylte QC-kriteriene
29. juni 2026
Først lagt ut (Faktiske)
6. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
21. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
20. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026-11/131
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
De-identified individual participant data will be available upon reasonable request to the corresponding investigator.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .